Proactive Investors - Run By Investors For Investors

AusCann Group substantial shareholder lifts interest to 13.28%

Canopy Growth Corporation has exercised options valued at more than $1.535 million and now holds in excess of 42 million shares.
Cannabis leaves and medical bottles
AC8 is well advanced in delivering a strategy to develop and produce cannabinoid pharmaceuticals

AusCann Group Holdings Ltd (ASX:AC8) substantial shareholder Canopy Growth Corporation has lifted its interest in the cannabinoid pharmaceuticals developer to 13.28%.

This came about on June 10 when the Ontario, Canada-based investor exercised more than 7.677 million options at 20 cents each for consideration of in excess of $1.535 million.

Canopy, through its Australian subsidiaries - Canopy Growth Australia Pty Ltd, Canopy Growth APAC Holdings Pty Ltd and Canopy Growth Farms Australia Pty Ltd – now holds more than 42 million shares.

AusCann is targeting the treatment of chronic pain in Australia while exploring global export opportunities and expansion into additional medical areas.

READ: AusCann Group's new chief executive officer Ido Kanyon takes up role

Last month the company’s new CEO Ido Kanyon took up his new position following a comprehensive international executive search conducted by the board.

With more than 15 years of experience in pharmaceutical and medical device businesses, Kanyon has launched innovative medicines globally covering a range of commercial strategies from digital health solutions to innovative biologics.

Strong growth platform

At the time he said: “I am excited to have formally joined the team at AusCann.

“I see tremendous opportunity for AusCann to lead in the delivery of cannabis-based pharmaceutical solutions that are endorsed by physicians and address the needs of patients who are suffering from inadequately treated medical conditions.

“The company has built a strong platform on which we will continue to grow.”

READ: AusCann Group continues transition into pharmaceutical manufacturing and sales company

Kanyon added: “We have begun a comprehensive review of our strategic priorities, which will help us tailor our operating plans to ensure we deliver the positive healthcare outcomes and shareholder returns we are seeking.”

AusCann remains on track to deliver its hard-shell capsules to the market for clinical trials during 2019.

Shares today are trading at 36.5 cents, up almost 3% on yesterday’s close.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

cannabis facility
January 23 2019
The company is breaking into the large and lucrative market in the golden state
medical cannabis concept
February 10 2019
AusCann is a fully integrated early-mover pharmaceutical cannabinoid company.
Cannabis leaf
November 19 2018
With the legalisation of recreational cannabis in Canada in October, and the US expected to follow suit, the company has its sights set on building up the very best in the industry

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use